Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections

State of the Art

Economic Impact of Antimicrobial Resistance

John E. McGowanComments to Author 
Author affiliation: Emory University School of Medicine, Atlanta, Georgia, USA

Main Article

Table 4

Elements of the economic impact of measures to deal with antimicrobial drug resistance, by perspective affected

Element Measurementa Perspective affected directly
Develop new antimicrobial agents Costs associated with drug development - Profit resulting from new drug's use Drug industry, HCB, patient, society
Conduct surveillance Cost of surveillance for infected and colonized patients (R) - Cost of surveillance for infected and colonized patients (S) HCB
Implement isolation Costs associated with barrier isolation (R) - Costs associated with barrier isolation (S) HCW, visitor, patient, HCB
Adapt lab procedures Costs associated with testing (R) - Costs associated with testing (S) HCB, patient, society
Educate about resistance Costs associated with educational programs (staff, patients) (R) -Costs associated with educational programs (staff, patients) (S) HCW, patient, visitor, HCB
Improve drug administration Costs for programs to improve drug administration (R) - Costs for programs to improve drug administration (S) HCW, HCB
Improve drug choice Costs for programs to improve drug choice (R) - Costs for programs to improve drug choice (S) Prescribers, HCB

aR = extent in patients infected with resistant organism; S = extent in patients infected with susceptible organism; HCB = health-care business; HCW = health-care workers.

Main Article

Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."

TOP